Krystal Biotech's Germany Pricing Drag Tests Whether Vyjuvek Demand Can Carry Q3

Krystal Biotech heads into its third-quarter report with a split personality. Underneath, nearly every demand signal has been moving the right way: US reimbursement approvals have climbed past 730, gross margin sits near 95%, and cash has swelled beyond $1.1 billion. On the surface, however, reported European revenue has gone flat because of a pricing reserve in Germany, and management warned last quarter that the drag would linger through this report. The question for Monday morning is whether US momentum and underlying vial growth are strong enough to show through that accounting fog.

Wall Street is looking for revenue of about $124.7 million, up 27.5% from $97.8 million a year ago and roughly 5% above last quarter's $119.2 million. That sequential step is in line with the steady but unspectacular climb Krystal has posted for four straight quarters, so the bar is not heroic. Earnings are a different story on paper. Consensus calls for $1.84 per share, a hair above last quarter's $1.79 but about 31% below the $2.66 earned a year earlier. With revenue growing briskly and margins firm, that year-over-year decline looks more like a tough comparison than a sign of operating deterioration, and the more useful benchmark is the sequential trend. Management has not offered revenue guidance, but it has reaffirmed its full-year non-GAAP R&D and SG&A outlook of $175 million to $195 million on every call this year. Spending landing comfortably within that range would keep the profit story intact.

Germany is the swing factor. Management expected price negotiations there to wrap up during the third quarter, with reported European revenue normalizing in the fourth. Confirmation that talks have closed on schedule, along with clarity on whether the final price lands near the accrued level, would validate the view that flat European revenue is a timing issue rather than a pricing problem. A delay, or a settlement that forces a larger reserve true-up, would push normalization into 2027 and weaken the claim that double-digit vial growth abroad will soon show up in the numbers. France is already slated for 2027, so investors have little patience for another European slip. Japan also deserves a look, since the early requirement for frequent prescription renewals poses a compliance risk that would surface as softer reorders.

In the US, the key is quality of growth. Krystal has already surpassed its initial penetration target, which means incremental gains now depend on retaining patients and adding milder cases. Management noted that new starts are skewing toward less severe disease, which may use less product, and that the start-stop treatment pattern makes any single quarter noisy. Continued gains in US net revenue from last quarter's $91.6 million would argue the franchise still has room to run, while a stall would raise questions about the shape of the long tail.

The pipeline adds another layer. The KB803 IOLITE study is fully enrolled with data promised this year, and an early look at KB707 in Gorlin syndrome is also expected. Any wobble in that timing would sting more because the NK program has already drifted toward early 2027.

Sentiment has improved somewhat, with readings less bearish than before the last report, yet the stock has slipped about 3% since then while the S&P 500 gained. At $311.50 it sits just above its 200-day average and nearer the bottom of its post-earnings range of roughly $297 to $373. That leaves room for relief if Germany is resolved cleanly. Ultimately, this report hinges on whether management can credibly show that the European softness is temporary while the US engine keeps compounding.

This earnings preview was originally published on Earnings Whispers.

This article is for informational purposes only and is not investment advice. Earnings Whispers and its staff may hold positions in the securities mentioned. It was generated automatically, with the help of AI, from Earnings Whispers and company data, and checked by Earnings Whispers before publication.